Ixekizumab in children with active psoriatic and enthesitis-related juvenile idiopathic arthritis (COSPIRIT-JIA): a multicentre, open-label, 16-week, Bayesian trial including a randomised reference group to adalimumab
Authors' conclusion
Ixekizumab was well tolerated and effective for the treatment of children with enthesitis-related arthritis and juvenile psoriatic arthritis who are candidates for biological DMARD therapy.
Study context
- Population
- Children with enthesitis-related arthritis (aged 6 to <18 years) or juvenile psoriatic arthritis (aged 2 to <18 years) with ≥3 active peripheral joints and bodyweight ≥10 kg40 randomised 1:1
- Participants
- 101 children
- Comparison
- Ixekizumab vs adalimumab
- Ixekizumabn = 81
- Adalimumabn = 20reference
- Primary endpoint
- Percentage of ixekizumab-treated participants meeting JIA-ACR30 response criteria
- Follow-up
- Week 16
Methodological detailsmulticentre, Bayesian analysis, randomised adalimumab reference group, ongoing
- Multicentre
- Bayesian analysis
- Randomised adalimumab reference group
- Ongoing
Primary result
As reported in the abstract
JIA-ACR30 response with ixekizumab
Safety
- Treatment-emergent adverse events, ixekizumab
- 46% · mild · moderate 36% · severe 0
Treatment-emergent adverse events, ixekizumab
- Safety profile consistent with adult PsA or SpA and paediatric psoriasis indications
Original publication
Ixekizumab in children with active psoriatic and enthesitis-related juvenile idiopathic arthritis (COSPIRIT-JIA): a multicentre, open-label, 16-week, Bayesian trial including a randomised reference group to adalimumab. Lancet Rheumatol. Published 2 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →